Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Xarelto: Investigational Agent for Treatment and Prevention of Thromboembolic Events

Drug (Brand / Generic)

Xarelto / rivaroxaban

Company / Licensee

Bayer and Johnson & Johnson

Therapy Class

Anticoagulant

Product Description

Selective inhibitor of coagulation Factor Xa

Current Indication

Primary prevention and treatment of VTE following orthopaedic surgery

Market Sector

Cardiovascular

Development Status

Approved in Europe and US
Expand
Close
Close
Close

Go Top